At a median follow-up of @ months ( IQR @-@ @ ) , @ ( @ % ) of the prespecified @ death events for the final analysis had been observed : @ ( @ % ) of @ patients in the abiraterone acetate group and @ ( @ % ) of @ in the placebo group .